Painchek PCK.ASX One to watch?

[Carpenterjoe]

Key points from latest quarterly.

64,000 global commercial beds contracted, a 127% increase compared to prior corresponding period
(PCP).

78% increase in cash receipts to $551,000 in Q3 FY23 vs PCP, with YTD cash receipts up 153% to
$1,504,000.

Cumulative Painchek pain assessments exceed 2,300,000 as of 31 March.

Circa 3500 pain assessments conducted daily.

PainChek is currently achieving 84% licence retention rates

PainChek is targeting US FDA clearance for market entry in 2024.

PainChek is now in communication with the Japanese regulatory authorities (PMDA) to determine
regulatory process and requirements.

Capital raise or finance needed in 3/6 months

[Carpenterjoe]

Key points from latest quarterly.

96% increase in global contracted bed licences over prior year to 70,000 commercial licences across
more than 1,000 aged care facilities in ANZ, UK and initial sales in Canada.

85% client retention rate on annual renewal

A 90% increase in annual customer receipts to $2,241,000, with Q4 FY23 increasing 26% to $737,000 vs
PCP and up 33% vs Q3 FY23.

R&D incentive $1,049,000 was received in the quarter.

Cumulative PainChek pain assessments exceed 2,900,000 as of 30 June – an increase of 115% over the
previous year.

Depending on what numbers you use, this equates to 5000-6600 daily pain assessments.

Finance/CR will need to be sorted this quarter. Bring on the north American market and FDA approval.

[Carpenterjoe]

Nice results out of Scotland,

after 12 weeks falls within the home had reduced by 75% and episodes of stress and distress had reduced by 42%